Text Size

A Study to Determine the Variability of a 6-Minute Walk Test in Cystic Fibrosis Subjects With Advanced Lung Disease

This study has been completed.
Sponsor:
Information provided by:
Genentech
ClinicalTrials.gov Identifier:
NCT00311506
First received: March 25, 2006
Last updated: April 4, 2006
Last verified: April 2006
History of Changes
  Purpose

This is an observational study to be conducted at approximately 25 sites in the United States. Approximately 25 subjects with severe obstructive CF lung disease (FVC <40% predicted) will be enrolled.


Condition Phase
Cystic Fibrosis
 Phase 4

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: A Study to Determine the Variability of a 6-Minute Walk Test in Cystic Fibrosis Subjects With Advanced Lung Disease

Resource links provided by NLM:

MedlinePlus related topics: Cystic Fibrosis
U.S. FDA Resources

Further study details as provided by Genentech:

Estimated Enrollment: 25
  Eligibility

Ages Eligible for Study:   14 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Able to provide written informed consent
  • Males or females who will be >=14 years old at Visit 3
  • A proven diagnosis of CF as evidenced by a positive sweat test (sweat sodium or chloride >60 mEq/L by quantitative pilocarpine iontophoresis), or genotype and clinical symptoms consistent with the diagnosis of CF
  • Able to perform reproducible spirometry maneuvers at Visit 1 in accordance with the American Thoracic Society (coefficient of variation for three FEV1 maneuvers <=0.2)
  • FVC <40% predicted for height, age and sex at Visit 1
  • On a stable regimen of chest physiotherapy (CPT) begun at least 7 days prior to Visit 1
  • Able to complete the 6-minute walk test at Visit 1

Exclusion Criteria:

  • Use of an investigational drug or device within 28 days prior to Visit 1
  • Experiencing an episode of severe acute respiratory failure, as determined by the investigator
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00311506

Sponsors and Collaborators
Genentech
Investigators
Study Director: Morris Cheeks, M.D. Genentech
  More Information

Additional Information:
Study Results  This link exits the ClinicalTrials.gov site

No publications provided

ClinicalTrials.gov Identifier: NCT00311506     History of Changes
Other Study ID Numbers: Z1943n
Study First Received: March 25, 2006
Last Updated: April 4, 2006
Health Authority: United States: Institutional Review Board

Keywords provided by Genentech:
Pulmozyme

Additional relevant MeSH terms:
Cystic Fibrosis
Fibrosis
Lung Diseases
Pancreatic Diseases
Digestive System Diseases
 Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on May 16, 2013